N-acetyl mannosammine as a therapeutic agent
The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.
1. A method of treating a condition or disease in a mammal in need thereof comprising selecting a subject with the condition or disease, and administering to the subject an effective amount of N-acetyl mannosamine or a derivative thereof, to the mammal, wherein the derivative consists of Formula I.
wherein R 1 , R 3 , R 4 , or R 5 is hydrogen, lower alkanoyl, carboxylate or lower alkyl; R 2 is lower alkyl, lower alkanoylalkyl, lower alkyl alkanoyloxy; and the condition or disease is diabetic nephropathy.
2. The method of claim 1 , comprising administering a therapeutic amount of N-acetyl mannosamine to the mammal.
3. The method of claim 2 , wherein the therapeutic amount is about 0.1 g to about 50 g N-acetyl mannosamine per day.
4. The method of claim 2 , wherein the therapeutic amount is administered in a unit dosage of about 0.01 g to about 50 g N-acetyl mannosamine per unit dosage.
5. The method of claim 1 , comprising sustained release of the sialic acid precursor, N-acetyl mannosamine or a derivative thereof.
6. The method of claim 1 , comprising topical administration of the sialic acid precursor, N-acetyl mannosamine or a derivative thereof.
7. The method of claims 2 , wherein the N-acetyl mannosamine is administered orally to the mammal.
8. The method of claim 2 , wherein the N-acetyl mannosamine is microencapsulated.
9. The method of claim 2 , wherein the method decreases proteinuria in the mammal.